(PRWEB) July 04, 2014
In just under a month, more than 165 new DePuy Pinnacle hip lawsuits (http://www.depuypinnacle-lawsuit.com/) have been added to a federal metal-on-metal hip litigation currently underway in the U.S. District Court, Northern District of Texas, Bernstein Liebhard LLP reports.
According to documents published July 1st on the multidistrict litigation’s website, a total of 6,383 cases involving a metal-on-metal version of the DePuy Pinnacle Hip Replacement System are now filed in the federal proceeding. This version includes a metal Ultamet liner, which has been associated with pain, swelling, symptoms associated with metallosis (metal ion poisoning) and early premature device failure complications. When court documents were last updated on June 5th, a total of 6,218 Pinnacle hip lawsuits had been filed, representing significant growth in the multidistrict litigation. (In re: DePuy Orthopaedics Inc. Pinnacle Hip Implant Product Liability Litigation, MDL No. 2244)
“We are pleased to see the number of Pinnacle hip lawsuits is continuing to increase in the Northern District of Texas, as our Firm hears on a regular basis from individuals who were allegedly injured by the metal hip replacement,” says Bernstein Liebhard LLP, a nationwide law firm representing victims of defective drugs and medical devices. The Firm is currently offering free and confidential case reviews to individuals who may have sustained injuries as a result of the all-metal Pinnacle hip.
DePuy Pinnacle Hip Lawsuits
More than 6,300 lawsuits now filed in the federal DePuy Pinnacle hip litigation similarly accuse the Johnson & Johnson subsidiary, DePuy Orthopaedics, of failing to adequately warn doctors and patients about side effects that may stem from implantation of the hip, as well as test it for safety and effectiveness. Given the implant’s metal-on-metal design, plaintiffs similarly allege that toxic metal debris can seep into the recipients’ tissue and blood stream, causing chronic pain, metallosis, the formation of pseudotumors and other complications indicating premature device failure.
Jeffrey S. Grand, a partner with Bernstein Liebhard LLP, is an active member of the Plaintiffs’ Steering Committee in the federal Pinnacle litigation, which is expected to begin its first federal trial in September 2014.
More than a year ago, Johnson and Johnson and DePuy Orthopaedics announced that it would cease sales of its metal-on-metal hip replacements, including the all-metal Pinnacle. The company’s action in May 2013 followed a federal notice from the U.S. Food and Drug Administration (FDA) that revealed its intention to implement new rules that would require all-metal hip manufacturers to submit their products for pre-market approval. According to the January 2013 alert, the FDA warned that hip replacement devices part of this class were more likely to fail early than those made of other materials.*
Individuals who allegedly suffered early hip failure complications due to the DePuy Pinnacle hip may be eligible to receive compensation for medical bills, lost wages, pain and suffering and other injury-related damages. Learn more about filing a DePuy Pinnacle lawsuit when you visit Bernstein Liebhard LLP’s website. For a free case evaluation, please call 800-511-5092 today.
*bloomberg.com/news/2013-05-16/j-j-will-stop-sales-of-metal-on-metal-hip-replacements.html, Bloomberg.com, May 17, 2013
About Bernstein Liebhard LLP
Bernstein Liebhard LLP is a New York-based law firm exclusively representing injured persons in complex individual and class action lawsuits nationwide since 1993. As a national law firm, Bernstein Liebhard LLP possesses all of the legal and financial resources required to successfully challenge billion dollar pharmaceutical and medical device companies. As a result, our attorneys and legal staff have been able to recover more than $3 billion on behalf of our clients. The Firm has been named by The National Law Journal to the Plaintiffs’ Hot List, recognizing the top plaintiffs firms in the country, for the past 12 consecutive years. Bernstein Liebhard LLP is the only firm in the country to be named to this prestigious list every year since it was first published in 2003.
Bernstein Liebhard LLP represents the victims of defective drugs and medical devices on a contingency-fee basis, and our clients are never expected to pay attorneys fees unless their case results in a successful recovery on their behalf. New York State’s contingency fee cap rules generally limit those fees to 33 1/3% of the total recovery. As a result, the Firm’s fees can be significantly lower than those assessed by attorneys in other states, which depending on the law may amount to as much as 40% or more of a plaintiff’s recovery.
Bernstein Liebhard LLP
10 East 40th Street
New York, New York 10016
ATTORNEY ADVERTISING. © 2014 Bernstein Liebhard LLP. The law firm responsible for this advertisement is Bernstein Liebhard LLP, 10 East 40th Street, New York, New York 10016, 800-511-5092. Prior results do not guarantee or predict a similar outcome with respect to any future matter.
Felecia L. Stern, Esq.
Bernstein Liebhard LLP